pounds, showing a broad spectrum of antimicrobial and antitumor activities in murine models has been identified in cultures of Actinomadura verrucosospora ATCC 393341)2).
The isolation and structure elucidation of esperamicins Ax (esp Ax), Alb (esp Alb) and A2 (esp A2) have been reported1'3'40.
The esperamicins consist of a bicyclic core to which attached a trisaccharide and a substituted 2-deoxy-L-fucose. The bicyclic core contains an enediyne, an allylic trisulfide and a bridgehead eneone.
Esp AA (Fig. 1) , the major component of the esperamicin family isolated from the fermentation of A. verrucosospora ATCC39334 grown in the complex mediumH9465), is one of the most potent antitumor agents yet discovered2). Three minor esperamicins, esp A2, esp Alb and esp P ( Fig. 1) were also isolated from the large scale fermentation of A. verrucosospora ATCC 39334 grown in the complex medium5j6). While developing a defined medium for more efficient incorporation of labelled precursors into esp Ax during the biosynthetic studies7), we detected the formation of two new esperamicin analogs in a defined medium. We report here the production, isolation, structure determination and antitumor activity of these analogs. A vegetative culture ofA. verrucosospora ATCC39334 was prepared by transferring 4ml of the frozen stock culture to a 500-ml Erlenmeyer flask containing 100ml of a vegetative medium consisting of starch 2%, glucose 0.5%, Pharmamedia 1%, yeast extract 1% and CaCO3 0.2%. The vegetative culture was incubated at 28°C for 96 hours on a rotary shaker operating at 250rpm. An 8-ml aliquot of incubated seed culture was transferred to a 500-ml Erlenmeyer flask containing 100ml of complex medium H946. MediumH946 was prepared using cane molasses 6%, starch 2%, fish meal 2%, Using the same medium and conditions described above for the preparation of the seed culture, an 8-ml aliquot of incubated seed culture was transferred to a The purification of the two new analogs from a 10-liter fermentation broth is summarized in Fig. 4 . The structure determination of these two newanalogs is summarized in Fig. 5 . Mass spectrometry analysis shows that both analogs have identical molecular ions 28 mass unit less than that of esp A1 indicating a difference of two methylene groups. In addition, fragmentation of the glycosidic bond of the aminosugar residue results in formation of base peaks at m/z 144 that clearly identifies the alkylation pattern of the analyzed congeners (Fig.   5 ). Lack of availability in sufficient quantities, their instability, and the complexity of their NMRspectra precluded a full assignment of the chemical shifts for the minor components, yet the close structural relations among them allowed us to classify them based on a few readily identifiable diagnostic peaks. In the XH spectra the lowest three singlets at 1 1.77ppm (br, NH), 8.58 ppm (H-12iv), and 7.47ppm (H-9iv) are indicative of the Ax series, while the equivalent peaks for the A2series are found at ll.90, 8.61, and 7.57ppm, respectively (Fig. 5) . In the high field region of the esp Alc spectrum a doublet at 1.30ppm indicates the presence of 61V methyl group. The equivalent doublet for the A2ccongener was shifted to 1.24ppm ( The extracts and fractions from purification were evaporated to dryness in vacuo using a rotary evaporator at 25°C. Host: CDFi mice. Schedule: QlD x l; 2. Evaluation: Medium survival time (MST). Effect: % T/C = (MST treated/MST control) x 100. Criteria: % T/C > 125 considered significant antitumor activity. Control mice were given saline injection. Evaluation: Medium survival time (MST). Effect: % T/C=(MST treated/MST control) x 100. Criteria: % T/C > 125 considered significant antitumor activity. Control mice were given saline injection.
The in vivo antitumor activity of esp Al5 esp Alc and esp A2c against P388 leukemia implanted ip in mice is shown in Table 1 . The activity and potency of esp Alc against P388 leukemia are similar to those of esp A±and both of the compounds were active at the lowest dosage tested, 0.0005mg/kg/inj.
Esp A2c was active against P388 leukemia at 0.004mg/kg/inj but was inactive at 0.002mg/kg/inj, indicating that it is at least 8 fold less potent than esp A1and esp Alc based on minimal effective dose comparisons. Table 2 compares the effect of esp A1 and esp A2 against P388 leukemia implanted ip in mice. Esp A1 was again active at the lowest dosage tested, 0.00001 mg/kg/inj. Esp A2 was active against P388 leukemia at 0.0001 mg/kg/inj but was inactive at 0.00003mg/kg/inj, indicating that it is at least 10 fold less potent than esp A2 based on minimiumeffective dose comparisons. The above finding indicates that the position of attachment of the anthranilate chromophore to the 2-deoxy-L-fucose moiety is an important factor in determining the antitumor potency of esperamicins.
Mechanismof action studies10) demonstrated that the anthranilate-deoxyfucose moiety affects the uptake of the drug into the cells and after activation mayalso sterically hinder the resulting phenylene diradical so as to lead to inefficient double stranded breakage of DNA.Furthermore, results from molecular dynamics simulations and spectroscopic studies1 1~13) showed that the anthranilatedeoxyfucose moiety contributes significantly to the biochemistry of esp Ax-induced DNAdamage.
In this paper, we have demonstrated that new esperamicin analogs can be generated by changing the composition of the fermentation medium. The comparison of antitumor activity between esp Alc and esp A2c also confirms that the A1series are more potent than the A2 series ofesperamicin in the in vivo antitumor tests.
